<DOC>
	<DOCNO>NCT01366326</DOCNO>
	<brief_summary>MNTX 1109 single center , open label study , compose normal healthy adult subject evaluate PK MNTX metabolite administer daily subcutaneous ( SC ) injection period seven day . Blood sample obtain screen drug concentration data .</brief_summary>
	<brief_title>Evaluate Pharmacokinetics ( PK ) Methylnaltrexone ( MNTX ) Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>1 . Body weight â‰¥40 kg ( 88 lb ) 2 . In good health clinically significant abnormal finding physical examination , medical history screen 12lead ECG 3 . Nonsmoker 4 . Has know allergy study drug relate chemicallyrelated compound ( i.e . naltrexone , naloxone ) . 1 . History clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric , cardiovascular disease 2 . History clinically significant allergy 3 . Positive urine screen drug 4 . History positive blood screen human immunodeficiency virus ( HIV ) , hepatitis B virus ( Hep B ) , hepatitis C virus ( HCV ) 5 . Prior exposure , allergy know hypersensitivity methylnaltrexone 6 . Diagnosis alcohol substance dependence within past 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>